In mid-November, the National Medicines Safety Agency (ANSM) organized a meeting in the presence of user representatives cyproterone acetate (the drug Androcur and its generic versions) as well as health professionals and health insurance, in order to discuss the risks of meningioma associated with the use of these drugs.
To improve patient care, the following measures have been taken:
-
The establishment of an annual care agreement form, essential for any dispensing of the drug in pharmacies. This care agreement form will be co-signed by the patient and the prescriber.
The distribution, from the beginning of 2019, of an information document intended for patients currently treated or considering treatment with cyproterone acetate.
Sending a letter to the attention of all doctors who have prescribed cyproterone acetate in the last 24 months (by the end of the first half of 2019).
“The combination of these measures will make the use of Androcur and its generics more secure” underlines the ANSM, which recalls that a toll-free number is already available to patients. “This number (0 805 04 01 10) is accessible free of charge from Monday to Friday from 9 am to 7 pm” indicates the ANSM.
Read also :
Meningioma: what is it exactly?
More brain tumors among graduates
